

# RISK RETURN ANALYSIS OF THE TOP PHARMACEUTICAL INDUSTRIES

## Abstract

This study analyzes the risk-return characteristics of the pharmaceutical industry, using data from NSE Finance Index and Moneycontrol.com. It focuses on five selected pharmaceutical companies over a decade, aiming to provide investors with a comprehensive understanding of their risk-return profile. The analysis uses financial ratios like ROI, ROE, and Beta to assess the unique risks and opportunities faced by pharmaceutical companies in the financial services sector. The study employs regression equations and average returns to determine the level of risk associated with each company and identify those with the highest returns. The anticipated outcome is valuable insights for investors seeking to maximize returns while effectively managing risks. The ranking of sample pharmaceutical companies based on their returns will help identify companies with strong performance and potential for future success. This research contributes to existing literature on risk-return analysis in the pharmaceutical industry, providing useful information to investors, financial analysts, and stakeholders. By enhancing understanding of the risk and return characteristics of pharmaceutical companies, it supports stakeholders in making informed investment decisions in this sector.

**Keywords:** Risk-return Analysis, ROI, ROE, Pharmaceutical Companies, Stakeholders and Financial analysts.

## Authors

### Preetham Kumar B

Department of Biotechnology  
AJK College of Arts and Science  
Coimbatore, Tamil Nadu, India.  
preetham24102000@gmail.com

### Guna Sekar S

Department of Management Studies  
AIMS International Business School  
Bangalore, Karnataka, India.

## I. INTRODUCTION

The pharmaceutical industry is crucial in healthcare, focusing on developing and manufacturing drugs that improve and save lives. **Perikala, n., & reddy, n.r. (2019)** Understanding the risk and return characteristics of pharmaceutical companies is essential for making informed investment decisions. This study aims to conduct a comprehensive risk-return analysis of selected companies, including Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., and Dr. Reddys

Laboratories Ltd., Cipla Ltd., and Apollo Hospitals Enterprise Ltd. The analysis will provide a holistic understanding of the companies' financial health and performance, allowing investors to assess potential rewards and risks associated with investing in them. **Kumar, V.L., & Jyothi, S.A. (2022)** The study will use quantitative analysis, financial modeling, and statistical techniques to gather relevant financial data from reputable sources and employ established risk and return metrics to assess risk exposure and measure return efficiency. This will help identify companies that have delivered superior returns relative to the market and those that have lagged behind. This analysis will provide valuable insights for investors, financial analysts, and stakeholders in the pharmaceutical sector, enabling them to make informed investment decisions and develop strategies to optimize risk-adjusted returns.

## II. OBJECTIVES OF THE STUDY

- To analyze the risk and return of chosen pharmaceutical companies covered by the NSE Finance Index.
- To compare the performance and rank based on the returns yield of the selected companies with market returns for 10 financial years from 2013 to 2023.

## III.SCOPE OF THE STUDY

The analysis will focus on calculating the risk-return profile of these companies to identify which ones have provided the maximum returns. By analyzing financial ratios such as ROI, ROE, and Beta, investors can understand the calculation of risk-return for investing in any firm. The study will rank the sample companies' stock based on the returns yielded, helping to identify the companies that have delivered the highest returns and can potentially continue to do so in the future. Overall, the study will contribute to existing literature on risk-return analysis in the pharmaceutical industry and benefit investors, financial analysts, and other stakeholders interested in this sector.

## IV. LITERATURE REVIEW

1. **Dolgaia, A.A., & Sorokina, V.V.(2023):** This research aims to find out the peculiarities of information technology (IT) companies as an object of investment attractiveness assessment, present and apply alternative approaches to the evaluation of the investment attractiveness of these companies based on internal and external factors. The paper examines the peculiarities of IT companies, their activities' results, and existing methods for evaluating investment attractiveness. Data was obtained from the analysis of external and internal factors of the investment attractiveness of Yandex for the period from 2019 to 2022. The key conclusion is that to make investment decisions, a comprehensive assessment are required, including considering external & internal factors.

2. **Agung, D., & Widodo, H. (2023):** This study aims to analyze the effect of the ex-date dividend on the market reaction. It used a descriptive method to select 6 companies in the manufacturing sector for 5 periods 2016-2020. The data analysis method used was the paired sample test for abnormal returns and the Wilcoxon signed rank test on trading volume activity. The results showed that there was a difference between before and after the ex-date dividend, with the Wilcoxon signed rank test showing a difference between before and after the dividend.
3. **Kumar, V.L., & Jyothi, S.A. (2022):** This paper aims to evaluate the long-term performance of selected equity stocks of the Pharma industry on a long-term basis. It uses tools such as standard deviation, Beta and Average returns to calculate the risk and return of selected Pharma stocks. The Pharma Sector is important in the Indian Economy, and stock markets play a major role in the up-liftment of the Indian Economy. This paper evaluates the long-term performance of the Pharma industry by evaluating selected Pharma stocks on the basis of statistical tools. The time period for evaluation is 5 years.
4. **Rahman, H., & Hussain, S. (2022):** This study aims to empirically explore the proper volatility models of five pharmaceutical companies listed in the DSE, Bangladesh. The data covers 667 days daily log returns calculated based on closing prices of these five companies from 28th January 2019 to 30th December 2021. Based on model selection criteria AIC, SBIC, Log-Likelihood, and residual diagnostics, GARCH(1,1) is considered to be more appropriate models for both Square Pharmaceuticals Ltd., and Beacon Pharmaceuticals Ltd., EGARCH(1,1) is best for both IBN SINA and Orion Pharmaceuticals Ltd., and any of the GARCH(1,1), and TGARCH(1,) can be applied for the volatility estimation of Beximco Pharmaceuticals Ltd.
5. **Hidayana, R.A., Napitupulu, H., & Sukono, S. (2022):** This paper aims to predict the return and risk of stock asymmetry using a time series model approach. It is based on the Autoregressive Integrated Moving Average-Glosten Jagannatan Runkle-Generalized Autoregressive Conditional Heteroscedasticity (ARIMA-GJR-GARCH) model and the Value-at-Risk (VaR) model. The data analyzed are the best ten stocks according to the criteria that apply on the IDX, the period between 17 December 2018 to 14 December 2021. The analysis results show that of the best ten stocks, those with relatively better performance are PTBA, TLKM, UNVR and BBKA stocks. Based on the results of this analysis, it can be used as a reference in making investment decisions for investors, specifically investing in the ten stocks analyzed.
6. **Chandavar, V., Gadade, K., & Patil, S. (2022):** Portfolio construction is the process of choosing securities with the lowest risk in order to get the highest returns. This study aims to formulate portfolios based on assessment of volatility. Data from S&P BSE listed 30 companies was collected from secondary sources and all 30 companies were divided into three portfolios. The hypothesis was tested and Sharpe's, Treynor's and Jensen's Performance Measure were calculated and Portfolio's were ranked. It was concluded that when volatility 0.5, there is no significant impact of volatility on portfolio performance, whereas the portfolio with volatility more than one has reported significant impact of volatility on its performance.
7. **Robbyah, & et al. (2021):** This study aims to determine the risk and return on investment in insurance companies and analyze the effect of macroeconomic variables on the level of

risk and return on investment. The sampling technique used was purposive sampling. Data analysis showed that Asuransi Jasa Tania Tbk has the highest level of conclusion, 22.3%, and Asuransi Harta Aman Pratama Tbk. has the lowest rate of -3.3%. For three years, the value of Gross Domestic Product has increased successively, causing a stock return proportional to the level of risk. Changes in the inflation rate up and down for three consecutive years have a different effect every year, where when the inflation rate decreases, the rate of return on investment will be high. Additionally, the interest rate decreased from 4.75% in 2016 to 4.25% in 2017, then increased to 6.00% in 2018. The Rupiah exchange rate against the dollar is getting weaker, indicating an increase in the exchange rate. When the rupiah exchange rate weakens, people will choose to invest in foreign currencies because the value of these foreign currencies can determine the size of the risk.

8. **Siagian, A.O., et al. (2021):** This research aims to determine the influence of Current Ratio (CR), Debt to Asset Ratio (DAR), and Return on Equity (ROE) on Stock Price of pharmaceutical companies listed on the Indonesia Stock Exchange (IDX) 2016-2019 period. Data was taken from the IDX website and analysis prerequisite tests included normality test, multicollinearity, heteroscedasticity, and autocorrelation. Statistical results showed that current ratio (X1) and return on equity (X3) partially have a positive and significant effect on stock prices (Y). Debt to asset ratio (X2) partially does not have a significant effect on stock prices (Y). Simultaneously current ratio (X1), debt to asset ratio (X2), and return on equity (X3) have a positive and significant effect on stock prices (Y).
9. **Sureshkumar, V., & Balasubramanian, P. (2021):** This study aims to determine the effect of risk profile variables measured by the Non-Performing Loan (NPL) and Loan to Deposit Ratio (LDR), variable earnings as measured by Return on Assets (ROA) and Cost Operational and Operating Income (BOPO) as well as the measured capital variables with Capital Adequacy Ratio (CAR) on profit growth. The population in the study includes 8 banking companies listed on the Indonesia Stock Exchange 2013-2017. Data was derived from financial statements obtained from Bank Indonesia (BI) which may be accessed through [www.bi.go.id](http://www.bi.go.id) and [www.idx.co.id](http://www.idx.co.id). Data analysis used multiple linear regressions. The result of the research showed that there are variables that have positive effect to return of stock, CAR variable, ROE, and BOPO variable, while variable ROA and LDR have no effect on profit growth, and NPL has negative effect to return of stock. Ability variable independent in explaining the variation of the dependent variable equal to 57.6%, whereas the remaining 41.5% is explained by other independent variables outside the model research.

## V. DATA ANALYSIS

The study aims to analyze the risk and return of five selected pharmaceutical companies using data collected from two sources, namely, NSE and Moneycontrol.com. The data collection tool includes stock market data of the decade for these companies. The study employs several analysis tools, namely, Regression equation, and average returns. The primary goal of the study is to determine which of the five selected pharmaceutical companies provide more returns, and the level of risk associated with each company. The data analysis is made with the help of the data from the NSB website of the selected companies (Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Dr. Reddy's Laboratories Ltd,

Cipla Ltd, and Apollo Hospitals Enterprise Ltd) and for 10 financial years from 2013-2014 to 2022-2023. The opening stock of the company is considered as 1st April and the closing date is 31st of March.

**List of companies**

- Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd,
- Dr. Reddy’s Laboratories Ltd, Cipla Ltd,
- Apollo Hospitals Enterprise Ltd.

**Table 1: NSB market return value**

| <b>NSB NIFTY 50</b> |                           |                            |                |
|---------------------|---------------------------|----------------------------|----------------|
| <b>Years</b>        | <b>1<sup>st</sup> Apr</b> | <b>31<sup>st</sup> Mar</b> | <b>Returns</b> |
| <b>2013-2014</b>    | 5,704.40                  | 6,704.20                   | 17.527         |
| <b>2014-2015</b>    | 6,721.05                  | 8,491.00                   | 26.334         |
| <b>2015-2016</b>    | 8,586.25                  | 7,738.40                   | -9.875         |
| <b>2016-2017</b>    | 7,713.05                  | 9,173.75                   | 18.938         |
| <b>2017-2018</b>    | 9,237.85                  | 10,113.70                  | 9.481          |
| <b>2018-2019</b>    | 10,211.80                 | 11,570.00                  | 13.300         |
| <b>2019-2020</b>    | 11,669.15                 | 8,597.75                   | -26.321        |
| <b>2020-2021</b>    | 8,253.80                  | 14,690.70                  | 77.987         |
| <b>2021-2022</b>    | 14,867.35                 | 17,464.75                  | 17.470         |
| <b>2022-2023</b>    | 17,670.45                 | 17,464.75                  | -1.164         |

Calculation of Return Percentage

**Return = ((Closing price- Beginning Price)/Beginning Price)\*100**

2013-2014 = ((6,704.20 - 5,704.40)/5,704.40) \* 100 = 17.527

2014-2015 = ((8,491.00 - 6,721.05)/6,721.05) \* 100 = 26.334

**Table 2: Stock value of Sun Pharmaceutical Industries Ltd.**


| <b>Sun Pharmaceutical Industries Ltd.</b> |                           |                            |                |
|---|---------------------------|----------------------------|----------------|
| <b>Years</b>                              | <b>1<sup>st</sup> Apr</b> | <b>31<sup>st</sup> Mar</b> | <b>Returns</b> |
| <b>2013-2014</b>                          | 818.950                   | 563.200                    | -31.229        |
| <b>2014-2015</b>                          | 574.750                   | 1010.800                   | 75.868         |
| <b>2015-2016</b>                          | 1023.900                  | 811.700                    | -20.725        |
| <b>2016-2017</b>                          | 820.000                   | 687.050                    | -16.213        |
| <b>2017-2018</b>                          | 688.150                   | 505.100                    | -26.600        |
| <b>2018-2019</b>                          | 495.100                   | 475.450                    | -3.969         |
| <b>2019-2020</b>                          | 478.850                   | 332.700                    | -30.521        |
| <b>2020-2021</b>                          | 352.300                   | 595.700                    | 69.089         |
| <b>2021-2022</b>                          | 597.350                   | 920.600                    | 54.114         |
| <b>2022-2023</b>                          | 914.750                   | 991.900                    | 8.434          |

Calculation of Return Percentage

**Return = ((Closing price- Beginning Price)/Beginning Price)\*100**

2013-2014 = ((563.200 - 818.950)/818.950) \* 100 = -31.229

2014-2015 = ((1010.80 - 574.750)/574.750) \* 100 = 75.868



**Figure 1:** Stock value of Sun Pharmaceutical Industries Ltd.

The table below shows the financial performance of Sun Pharmaceutical Industries Ltd. over a period of ten years. The column "Returns" indicates the percentage change in the stock price of Sun Pharmaceutical Industries Ltd. during each fiscal year, with positive values indicating an increase in stock price, while negative values indicate a decrease.

The mean value of the returns is calculated to be 7.825%, and the standard deviation is 42.47729023%, indicating that the stock returns of Sun Pharmaceutical Industries Ltd. have experienced significant variability over the ten-year period. It is important to consider these factors when assessing the risk and potential return associated with investing in Sun Pharmaceutical Industries Ltd.

**Table 3: Calculation of Beta value of Sun Pharmaceutical Industries Ltd.**

| Market Value and Sun Pharmaceutical Industries Ltd |                |               |                 |                  |                 |
|--|----------------|---------------|-----------------|------------------|-----------------|
| Years  | X              | Y             | X <sup>2</sup>  | Y <sup>2</sup>   | XY              |
| 2013-2014  | 17.527         | -31.229       | 307.189         | 975.251          | -547.345        |
| 2014-2015  | 26.334         | 75.868        | 693.502         | 5755.918         | 1997.934        |
| 2015-2016  | -9.875         | -20.725       | 97.506          | 429.512          | 204.646         |
| 2016-2017  | 18.938         | -16.213       | 358.649         | 262.875          | -307.050        |
| 2017-2018  | 9.481          | -26.600       | 89.891          | 707.576          | -252.200        |
| 2018-2019  | 13.300         | -3.969        | 176.898         | 15.752           | -52.787         |
| 2019-2020  | -26.321        | -30.521       | 692.778         | 931.534          | 803.335         |
| 2020-2021  | 77.987         | 69.089        | 6081.989        | 4773.268         | 5388.039        |
| 2021-2022  | 17.470         | 54.114        | 305.218         | 2928.325         | 945.399         |
| 2022-2023  | -1.164         | 8.434         | 1.355           | 71.132           | -9.818          |
| <b>TOTAL</b>                                       | <b>143.679</b> | <b>78.247</b> | <b>8804.977</b> | <b>16851.145</b> | <b>8170.152</b> |

Calculation for the regression coefficient (Beta)

$$\beta = \frac{(n\sum XY - (\sum X)(\sum Y))}{(n\sum X^2 - (\sum X)^2)}$$

$$= \frac{(10(8170)) - (143.67 \times 78)}{(10 \times 8805) - (143^2)}$$

$$= \frac{(81700 - 11154)}{(88040 - 20449)}$$

$$= \frac{70546}{67591} \beta = 1.043$$

Therefore, for Sun Pharmaceutical Industries Ltd., the calculated Beta value of 1.675 suggests that the stock is relatively more volatile than the market. Investors should consider this level of volatility when assessing the risk and potential returns associated with investing in this company.

**Table 4: Stock value of Divis Laboratories Ltd.**

| Divis Laboratories Ltd. |                     |                      |         |
|-------------------------|---------------------|----------------------|---------|
| Years                   | 1 <sup>st</sup> Apr | 31 <sup>st</sup> Mar | Returns |
| 2013-2014               | 987.500             | 1359.500             | 37.671  |
| 2014-2015               | 1365.900            | 1810.050             | 32.517  |
| 2015-2016               | 1785.450            | 982.250              | -44.986 |
| 2016-2017               | 987.250             | 622.950              | -36.900 |
| 2017-2018               | 623.850             | 1087.650             | 74.345  |
| 2018-2019               | 1090.200            | 1654.550             | 51.766  |
| 2019-2020               | 1703.100            | 1893.900             | 11.203  |
| 2020-2021               | 1989.050            | 3584.250             | 80.199  |
| 2021-2022               | 3622.800            | 4538.600             | 25.279  |
| 2022-2023               | 4402.050            | 2820.250             | -35.933 |


Calculation of Return Percentage

$$\text{Return} = \frac{(\text{Closing price} - \text{Beginning Price})}{\text{Beginning Price}} \times 100$$

$$2013-2014 = \frac{(1359.500 - 987.500)}{987.500} \times 100 = 37.671$$

$$2014-2015 = \frac{(1810.050 - 1365.90)}{1365.90} \times 100 = 32.517$$

The table represents the financial performance of Divis Laboratories Ltd. over a period of ten years. The column "Returns" indicates the percentage change in the stock price of Divis Laboratories Ltd. during each fiscal year. The Trend of Returns suggests that the stock price experienced fluctuations over the observed period. The mean value of the returns is 19.516%, which is the average annual return of the company's stock during the period under consideration. The standard deviation is 45.64056315%, which highlights the volatility in the company's stock performance. It is important to consider these factors when assessing the risk and potential return associated with investing in Divis Laboratories Ltd.



**Figure 2:** Stock value of Divis Laboratories Ltd.

**Table 5: Calculation of Beta value of Divis Laboratories Ltd.**

| Market Value and Divis Laboratories Ltd. |                |                |                 |                  |                 |
|--|----------------|----------------|-----------------|------------------|-----------------|
| Years                                    | X              | Y              | X <sup>2</sup>  | Y <sup>2</sup>   | XY              |
| 2013-2014                                | 17.527         | 37.671         | 307.189         | 1419.096         | 660.251         |
| 2014-2015                                | 26.334         | 32.517         | 693.502         | 1057.357         | 856.317         |
| 2015-2016                                | -9.875         | -44.986        | 97.506          | 2023.727         | 444.213         |
| 2016-2017                                | 18.938         | -36.900        | 358.649         | 1361.646         | -698.823        |
| 2017-2018                                | 9.481          | 74.345         | 89.891          | 5527.148         | 704.871         |
| 2018-2019                                | 13.300         | 51.766         | 176.898         | 2679.691         | 688.500         |
| 2019-2020                                | -26.321        | 11.203         | 692.778         | 125.509          | -294.873        |
| 2020-2021                                | 77.987         | 80.199         | 6081.989        | 6431.894         | 6254.495        |
| 2021-2022                                | 17.470         | 25.279         | 305.218         | 639.017          | 441.633         |
| 2022-2023                                | -1.164         | -35.933        | 1.355           | 1291.199         | 41.830          |
| <b>TOTAL</b>                             | <b>143.679</b> | <b>195.160</b> | <b>8804.977</b> | <b>22556.284</b> | <b>9098.414</b> |

Calculation for the regression coefficient (Beta)

$$\beta = \frac{(n\sum XY - (\sum X)(\sum Y))}{(n\sum X^2 - (\sum X)^2)}$$

$$= \frac{(10(9098) - (143 \times 195))}{(10 \times 8805 - (143)^2)}$$


$$= \frac{(90980 - 27885)}{(88040 - 20449)}$$

$$= \frac{63095}{67591}$$

$$\beta = 0.933$$

Divis Laboratories Ltd.'s stock returns have a moderate positive correlation with the overall market, with a beta value of 0.933. This indicates that the stock tends to move in the same direction as the market, but with less volatility. This suggests that the stock tends to move in the same direction as the market, but with less volatility.





**Figure 3:** Market Value and Divis Laboratories Ltd.

**Table 6:** Stock value of Dr. Reddy’s Laboratories Ltd.

| <b>Dr. Reddy’s Laboratories Ltd.</b> |                           |                            |                |
|--------------------------------------|---------------------------|----------------------------|----------------|
| <b>Years</b>                         | <b>1<sup>st</sup> Apr</b> | <b>31<sup>st</sup> Mar</b> | <b>Returns</b> |
| <b>2013-2014</b>                     | 1766.500                  | 2625.800                   | 48.644         |
| <b>2014-2015</b>                     | 2563.900                  | 3425.300                   | 33.597         |
| <b>2015-2016</b>                     | 3488.750                  | 3015.650                   | -13.561        |
| <b>2016-2017</b>                     | 3035.200                  | 2613.250                   | -13.902        |
| <b>2017-2018</b>                     | 2632.350                  | 2102.450                   | -20.130        |
| <b>2018-2019</b>                     | 2080.550                  | 2717.200                   | 30.600         |
| <b>2019-2020</b>                     | 2780.250                  | 2994.250                   | 7.697          |
| <b>2020-2021</b>                     | 3120.750                  | 4518.200                   | 44.779         |
| <b>2021-2022</b>                     | 4516.000                  | 4354.400                   | -3.578         |
| <b>2022-2023</b>                     | 4295.450                  | 4567.800                   | 6.340          |

Calculation of Return Percentage

**Return = ((Closing price- Beginning Price)/Beginning Price)\*100**

2013-2014 = ((2625.800 - 1766.500)/1766.500) \* 100 = 48.644

2014-2015 = ((3425.300 - 2563.900)/2563.90) \* 100 = 33.597

The table represents the financial performance of Dr. Reddy’s Laboratories Ltd. over a period of ten years. The column "Returns" indicates the percentage change in the stock price of Dr. Reddy’s Laboratories Ltd. during each fiscal year. The Trend of Returns shows both positive and negative values across different years. The mean value of the returns is 12.049%, and the standard deviation is 25.55931611%. Overall, the table suggests that Dr. Reddy’s Laboratories Ltd. has experienced fluctuations in stock price over the years, with both positive and negative returns. The mean return indicates a moderate average annual return, while the standard deviation highlights the volatility in the company's stock performance. It is

important to consider these factors when assessing the risk and potential return associated with investing in Dr. Reddy's Laboratories Ltd.

**Table 7: Calculation of Beta value of Dr. Reddy's Laboratories Ltd.**

| <b>Market Value and Dr. Reddy's Laboratories Ltd.</b> |          |          |                      |                      |           |
|---|----------|----------|----------------------|----------------------|-----------|
| <b>Years</b>  | <b>X</b> | <b>Y</b> | <b>X<sup>2</sup></b> | <b>Y<sup>2</sup></b> | <b>XY</b> |
| <b>2013-2014</b>                                      | 17.527   | 48.644   | 307.189              | 2366.259             | 852.578   |
| <b>2014-2015</b>                                      | 26.334   | 33.597   | 693.502              | 1128.775             | 884.764   |
| <b>2015-2016</b>                                      | -9.875   | -13.561  | 97.506               | 183.893              | 133.906   |
| <b>2016-2017</b>                                      | 18.938   | -13.902  | 358.649              | 193.262              | -263.274  |
| <b>2017-2018</b>                                      | 9.481    | -20.130  | 89.891               | 405.229              | -190.857  |
| <b>2018-2019</b>                                      | 13.300   | 30.600   | 176.898              | 936.365              | 406.990   |
| <b>2019-2020</b>                                      | -26.321  | 7.697    | 692.778              | 59.246               | -202.594  |
| <b>2020-2021</b>                                      | 77.987   | 44.779   | 6081.989             | 2005.186             | 3492.208  |
| <b>2021-2022</b>                                      | 17.470   | -3.578   | 305.218              | 12.805               | -62.516   |
| <b>2022-2023</b>                                      | -1.164   | 6.340    | 1.355                | 40.201               | -7.381    |
| <b>TOTAL</b>  | 143.679  | 120.487  | 8804.977             | 7331.222             | 5043.824  |

Calculation for the regression coefficient (Beta)

$$\beta = \frac{(n\sum XY - (\sum X)(\sum Y))}{(n\sum X^2 - (\sum X)^2)}$$

$$= \frac{(10(5044) - (143 \times 120))}{(10 \times 8805 - (143)^2)}$$

$$= \frac{(50440 - 17160)}{(88040 - 20449)}$$

$$= \frac{33280}{67591}$$

$$\beta = 0.491$$

The regression coefficient (Beta) of 0.491 indicates the sensitivity of the company's stock returns (Y) to the overall market returns (X). A Beta value less than 1 suggests that the stock is less volatile than the market. Other factors, such as company-specific risks and market conditions, should also be considered when evaluating investment decisions.

**Table 8: Stock value of Cipla Ltd.**

| <b>Cipla Ltd.</b> |                           |                            |                |
|-------------------|---------------------------|----------------------------|----------------|
| <b>Years</b>      | <b>1<sup>st</sup> Apr</b> | <b>31<sup>st</sup> Mar</b> | <b>Returns</b> |
| <b>2013-2014</b>  | 379.750                   | 386.950                    | 1.896          |
| <b>2014-2015</b>  | 382.800                   | 702.200                    | 83.438         |
| <b>2015-2016</b>  | 712.450                   | 512.350                    | -28.086        |
| <b>2016-2017</b>  | 511.950                   | 598.350                    | 16.877         |
| <b>2017-2018</b>  | 592.950                   | 545.050                    | -8.078         |
| <b>2018-2019</b>  | 545.450                   | 525.600                    | -3.639         |
| <b>2019-2020</b>  | 528.900                   | 431.750                    | -18.368        |

|                  |          |          |         |
|------------------|----------|----------|---------|
| <b>2020-2021</b> | 422.850  | 812.200  | 92.078  |
| <b>2021-2022</b> | 815.100  | 1028.950 | 26.236  |
| <b>2022-2023</b> | 1018.050 | 887.700  | -12.804 |

Calculation of Return Percentage


**Return = ((Closing price- Beginning Price)/Beginning Price)\*100**

2013-2014 =  $((386.950 - 379.750)/379.750) * 100 = 1.896$

2014-2015 =  $((702.200 - 382.800)/382.800) * 100 = 83.438$

The table below shows the financial performance of Cipla Ltd. over a period of ten years. The column "Returns" indicates the percentage change in the stock price of Cipla Ltd. during each fiscal year. The Trend of Returns suggests that the stock price experienced fluctuations over the observed period.

The mean value of the returns is 14.955%, which is the average annual return of the company's stock during the period under consideration. The standard deviation is 41.56534081%, which highlights the volatility in the company's stock performance. It is important to consider these factors when assessing the risk and potential return associated with investing in Cipla Ltd.



**Figure 4:** Stock value of Cipla Ltd.

**Table 9:** Calculation of Beta value of Cipla Ltd.

| Market Value and Cipla Ltd. |        |         |                |                |          |
|-----------------------------|--------|---------|----------------|----------------|----------|
| Years                       | X      | Y       | X <sup>2</sup> | Y <sup>2</sup> | XY       |
| <b>2013-2014</b>            | 17.527 | 1.896   | 307.189        | 3.595          | 33.231   |
| <b>2014-2015</b>            | 26.334 | 83.438  | 693.502        | 6961.871       | 2197.287 |
| <b>2015-2016</b>            | -9.875 | -28.086 | 97.506         | 788.834        | 277.337  |
| <b>2016-2017</b>            | 18.938 | 16.877  | 358.649        | 284.821        | 319.611  |
| <b>2017-2018</b>            | 9.481  | -8.078  | 89.891         | 65.258         | -76.591  |

|                  |         |         |          |          |           |
|------------------|---------|---------|----------|----------|-----------|
| <b>2018-2019</b> | 13.300  | -3.639  | 176.898  | 13.244   | -48.402   |
| <b>2019-2020</b> | -26.321 | -18.368 | 692.778  | 337.395  | 483.467   |
| <b>2020-2021</b> | 77.987  | 92.078  | 6081.989 | 8478.29  | 7180.863  |
| <b>2021-2022</b> | 17.470  | 26.236  | 305.218  | 688.330  | 458.357   |
| <b>2022-2023</b> | -1.164  | -12.804 | 1.355    | 163.940  | 14.905    |
| <b>TOTAL</b>     | 143.679 | 149.548 | 8804.97  | 17785.56 | 10840.064 |

Calculation for the regression coefficient (Beta)

$$\beta = \frac{(n\sum XY - (\sum X)(\sum Y))}{(n\sum X^2 - (\sum X)^2)}$$

$$= \frac{(10(10840) - (143 \times 150))}{(10 \times 8805 - (143)^2)}$$

$$= \frac{(108400 - 21450)}{(88040 - 20449)}$$

$$= \frac{86950}{67591} \beta = 1.28$$

The computed regression coefficient (Beta) is 1.28. The sensitivity of a stock's returns to changes in the general market returns is measured by its beta. When the beta value exceeds 1, the stock is said to be more volatile than the market as a whole. In this instance, the computed beta value of 1.28 indicates that Cipla Ltd. is likely to experience more volatility than the market as a whole.

**Table 10: Stock value of Apollo Hospitals Enterprise Ltd.**

| <b>Apollo Hospitals Enterprise Ltd.</b> |                           |                            |                |
|---|---------------------------|----------------------------|----------------|
| <b>Years</b>                            | <b>1<sup>st</sup> Apr</b> | <b>31<sup>st</sup> Mar</b> | <b>Returns</b> |
| <b>2013-2014</b>                        | 838.900                   | 912.300                    | 8.750          |
| <b>2014-2015</b>                        | 916.450                   | 1340.550                   | 46.276         |
| <b>2015-2016</b>                        | 1369.200                  | 1320.850                   | -3.531         |
| <b>2016-2017</b>                        | 1329.300                  | 1155.750                   | -13.056        |
| <b>2017-2018</b>                        | 1165.150                  | 1029.850                   | -11.612        |
| <b>2018-2019</b>                        | 1064.650                  | 1182.950                   | 11.112         |
| <b>2019-2020</b>                        | 1227.600                  | 1098.250                   | -10.537        |
| <b>2020-2021</b>                        | 1139.050                  | 2925.600                   | 156.846        |
| <b>2021-2022</b>                        | 2902.650                  | 4614.800                   | 58.986         |
| <b>2022-2023</b>                        | 4516.100                  | 4363.000                   | -3.390         |

Calculation of Return Percentage


$$\text{Return} = \frac{(\text{Closing price} - \text{Beginning Price})}{\text{Beginning Price}} \times 100$$

$$2013-2014 = \frac{(912.300 - 838.900)}{838.900} \times 100 = 8.750$$

$$2014-2015 = \frac{(1340.550 - 916.450)}{916.450} \times 100 = 46.276$$

$$2019-2020 = \frac{(1098.250 - 1227.600)}{1227.600} \times 100 = -10.537$$

The table represents the financial performance of Apollo Hospitals Enterprise Ltd. over a period of ten years. The column "Returns" indicates the percentage change in the stock price of Apollo Hospitals Enterprise Ltd. during each fiscal year. The Trend of Returns suggests that the stock price experienced fluctuations over the observed period. The mean value of the returns is 23.984%, which is the average annual return of the company's stock during the period under consideration. The standard deviation is 52.8196316%, which highlights the volatility in the company's stock performance. It is important to consider these factors when assessing the risk and potential return associated with investing in Apollo Hospitals Enterprise Ltd.



**Figure 5:** Stock value of Apollo Hospitals Enterprise Ltd.

**Table 11: Calculation of Beta value of Apollo Hospitals Enterprise Ltd.**

| Market Value and Apollo Hospitals Enterprise Ltd. |                |                |                 |                  |                  |
|---|----------------|----------------|-----------------|------------------|------------------|
| Years   | X              | Y              | X <sup>2</sup>  | Y <sup>2</sup>   | XY               |
| 2013-2014   | 17.527         | 8.750          | 307.189         | 76.555           | 153.352          |
| 2014-2015   | 26.334         | 46.276         | 693.502         | 2141.505         | 1218.662         |
| 2015-2016   | -9.875         | -3.531         | 97.506          | 12.470           | 34.869           |
| 2016-2017   | 18.938         | -13.056        | 358.649         | 170.452          | -247.250         |
| 2017-2018   | 9.481          | -11.612        | 89.891          | 134.844          | -110.097         |
| 2018-2019   | 13.300         | 11.112         | 176.898         | 123.468          | 147.788          |
| 2019-2020   | -26.321        | -10.537        | 692.778         | 111.025          | 277.336          |
| 2020-2021   | 77.987         | 156.846        | 6081.989        | 24600.548        | 12231.936        |
| 2021-2022   | 17.470         | 58.986         | 305.218         | 3479.319         | 1030.510         |
| 2022-2023   | -1.164         | -3.390         | 1.355           | 11.493           | 3.946            |
| <b>TOTAL</b>                                      | <b>143.679</b> | <b>239.843</b> | <b>8804.977</b> | <b>30861.678</b> | <b>14741.054</b> |

Calculation for the regression coefficient (Beta)

$$\beta = \frac{(n\sum XY - (\sum X)(\sum Y))}{(n\sum X^2 - (\sum X)^2)}$$

$$= \frac{(10(14741)) - (143 \times 240)}{(10 \times 8805) - (143^2)}$$

$$= (147410 - 35607) / (88040 - 20449)$$

$$= 111803 / 67591 \beta = 1.675$$

For Apollo Hospitals Enterprise Ltd., the computed regression coefficient (Beta) is roughly 1.675. This shows that the stock returns of the firm are forecast to fluctuate, on average, 1.675 times more than the market returns. If the stock's beta rating is higher than 1, it may be more volatile than the market as a whole.

## VI. DISCUSSION

**Table 12: Regression coefficient**

| Regression coefficient |                                    |      |
|------------------------|------------------------------------|------|
| Sl.No                  | Company                            | Rank |
| 1                      | Sun Pharmaceutical Industries Ltd. | 3    |
| 2                      | Divis Laboratories Ltd.            | 4    |
| 3                      | Dr. Reddy's Laboratories Ltd.      | 5    |
| 4                      | Cipla Ltd.                         | 2    |
| 5                      | Apollo Hospitals Enterprise Ltd.   | 1    |

Based on the regression coefficients and ranking of the selected pharmaceutical companies, the following interpretations can be made:

1. **Apollo Hospitals Enterprise Ltd. (Rank: 1, B value: 1.675):** Apollo Hospitals Enterprise Ltd. has the highest regression coefficient among the selected companies, indicating a strong positive relationship between its stock returns and market returns. This suggests that the company's stock performance tends to be more sensitive to overall market movements. It has demonstrated the highest stock return value among the companies, positioning it as the top performer in terms of returns.
2. **Cipla Ltd. (Rank: 2, B value: 1.28):** Cipla Ltd. has a relatively high regression coefficient, indicating a positive relationship between its stock returns and market returns. While not as strong as Apollo Hospitals Enterprise Ltd., Cipla has shown a significant impact of market movements on its stock performance. With a relatively high stock return value, Cipla secures the second rank among the selected companies.
3. **Sun Pharmaceutical Industries Ltd. (Rank: 3, B value: 1.043):** Sun Pharmaceutical Industries Ltd. exhibits a positive relationship between its stock returns and market returns, although slightly weaker compared to the top two companies. The company's regression coefficient suggests that market movements have a moderate influence on its stock performance. Sun Pharmaceutical Industries Ltd. secures the third rank based on its stock return value.
4. **Divis Laboratories Ltd. (Rank: 4, B value: 0.933):** Divis Laboratories Ltd. also demonstrates a positive relationship between its stock returns and market returns, but with a slightly lower regression coefficient. This indicates that market movements have a relatively lower impact on the company's stock performance compared to the top three companies. Divis Laboratories Ltd. secures the fourth rank based on its stock return value.

- 5. Dr. Reddy's Laboratories Ltd. (Rank: 5, B value: 0.491):** Dr. Reddy's Laboratories Ltd. has the lowest regression coefficient among the selected companies, suggesting a relatively weaker relationship between its stock returns and market returns. The company's stock performance appears to be less influenced by market movements compared to the other companies in the study. Dr. Reddy's Laboratories Ltd. secures the fifth rank based on its stock return value.

It is important to note that the interpretation of the ranking should consider additional factors and not rely solely on the regression coefficients. Factors such as financial health, business strategies, industry dynamics, and future growth prospects should be taken into account for a comprehensive evaluation of the companies.

The data provided in the tables for Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Divis Laboratories Ltd., Cipla Ltd., and Apollo Hospitals Enterprise Ltd. showed that stock returns varied over the observed period, with both positive and negative values. The mean return was 7.825%, indicating an average annual return for the company's stock. The standard deviation of 42.47729023% suggests a relatively high level of volatility in the stock returns. The mean return was 19.516%, indicating the average annual return for the stock. Cipla Ltd.'s stock returns exhibited fluctuations over the observed period, with the mean return being 14.955%, representing the average annual return for the stock.

Overall, the table suggests that Cipla Ltd. has shown fluctuations in stock price over the years, with both positive and negative returns. The mean return indicates an average annual return, while the high standard deviation highlights the volatility in the company's stock performance. Investors should consider these factors when assessing the risk and potential return associated with investing in Cipla Ltd.

## VII. SUGGESTIONS

Based on the findings from the analysis of the selected pharmaceutical companies, the following suggestions can be made for investors considering investment in the top 5 pharma companies in India.

- 1. Diversify Investments:** Since each company has its own risk-return profile, it is advisable for investors to diversify their investments across multiple pharma companies.
- 2. Consider Long-Term Performance:** Evaluate the long-term performance of the companies along with their stock returns.
- 3. Conduct Fundamental Analysis:** Apart from analyzing stock returns, investors should conduct thorough fundamental analysis of the top 5 pharma companies.
- 4. Seek Professional Advice:** Investors, especially those who are new to the pharma industry, should consider seeking advice from financial professionals or investment advisors who specialize in the healthcare or pharmaceutical sector.

## VIII. CONCLUSION

The risk-return analysis of selected pharmaceutical companies offers valuable insights into their performance and ranking based on stock returns. Each company has its own unique risk-return profile, which investors should consider when making investment decisions in the pharma industry. Apollo Hospitals Enterprise Ltd. has the highest average returns, followed by Cipla Ltd., Divis Laboratories Ltd., Sun Pharmaceutical Industries Ltd., and Dr. Reddy's Laboratories Ltd. However, past performance is not a guarantee of future returns, and investors should conduct thorough research before making any investment decisions. The analysis also reveals variations in the performance of these companies over the years, emphasizing the importance of considering long-term performance rather than relying solely on short-term trends.

Diversifying investments across multiple pharma companies can help mitigate risks and provide exposure to different segments of the industry. Fundamental analysis, including revenue growth, profitability, product pipeline, competitive advantage, and management expertise, is advised. Aligning investment decisions with risk tolerance and long-term financial goals is crucial. This study serves as a starting point for investors interested in the pharma industry, but additional research and analysis specific to individual investment objectives are crucial.

## REFERENCES

- [1] Agung, D., & Widodo, H. (2023). Analysis of Abnormal Returns and Trading Volume Activities Before and After Ex-Date Dividends in the Manufacturing Sector Listed on the IDX 2016-2020 Period. *Academia Open*.
- [2] Anur, V.F., Mufid, J.E., & Wulandari, D.S. (2022). Stock price analysis before and during the covid-19 pandemic (Case Study on Pharmaceutical Sub-Sector Listed on the Indonesia Stock Exchange). *Indikator: Jurnal Ilmiah Manajemen dan Bisnis*.
- [3] Anwar, A.P., Jasuni, A.Y., & Juniarso, A. (2021). Single Index Model Analysis for Optimum Portfolio in Pharmaceutical Companies Registered in Indonesia Stock Exchange. *Jurnal Riset Ekonomi Manajemen (REKOMEN)*.
- [4] Banerjee, A. (2022). An Empirical Risk and Return Analysis of Select Stocks in NASDAQ  
[2] 100. *Accounting and Finance Research*.
- [1] Chandavar, V., Gadade, K., & Patil, S. (2022). Risk-return Analysis and Portfolio Construction of S&P BSE-30 Listed Companies. *MUDRA: Journal of Finance and Accounting*.
- [2] Dai, Z., Kang, J., & Wen, F. (2021). Predicting stock returns: A risk measurement perspective. *International Review of Financial Analysis*, 74, 101676.
- [3] Dolgaia, A.A., & Sorokina, V.V. (2023). The Investment Analysis of IT Companies: A Case Study of Yandex. *Review of Business and Economics Studies*.
- [4] Heryanto, J., & Sukarno, D.S. (2023). Sector Rotation Investment Strategy by Implementing Piotroski F-Score and Markowitz Portfolio Theory for Portfolio Construction: Indonesia Stock Market 2020 to 2022. *International Journal of Current Science Research and Review*.
- [5] Hu, J., Sui, Y., & Ma, F. (2021). The Measurement Method of Investor Sentiment and Its Relationship with Stock Market. *Comput. Intell. Neurosci.*, 2021, 6672677:1-6672677:11.
- [6] Joghee, M.V. (2021). A Study on Risk and Return Analysis of Selected Banking Securities.
- [7] Kumar, V.L., & Jyothi, S.A. (2022). Risk – return evaluation of selected pharma stocks trading in nse. *Journal of Management and Science*.
- [8] Lobo, S., & Bhat, G. (2021). Risk Return Analysis of Selected Stocks of Indian Financial Sector. *Emerging Markets: Finance ejournal*.
- [9] Lubis, A., & Purwanto, P. (2022). Influence of financial ratios toward stock price of pharmaceutical companies in indonesia. *Journal of business studies and mangement review*.
- [10] Merkle, C., & Sextroh, C.J. (2021). Value and Momentum from Investors' Perspective: Evidence from Professionals' Risk-Ratings. *Capital Markets: Market Efficiency ejournal*.



- [11] Naveenan, R.V. (2019). Risk and Return Analysis of Portfolio Management Services of Reliance Nippon Asset Management Limited (RNAM).
- [12] Nurhakim, A., Yunita, I., & Iradianty, A. (2016). The effect of profitability and inflation on stock return at pharmaceutical industries at bei in the period of 2011-2014.
- [13] Perikala, n., & reddy, n.r. (2019). Risk return analysis of indian equity markets.
- [14] Popa, C., et al. (2018). Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries. *Frontiers in Pharmacology*, 9.
- [15] Qiao, G. (2023). Survival of the Fittest: The Long-run Productivity Analysis of the Listed Information Technology Companies in the US Stock Market. *Economics*, 17.
- [16] Rahman, H., & Hussain, S. (2022). Modeling Returns Volatility of Selected Pharmaceutical Companies Listed in DSE of Bangladesh with GARCH Methods. *International Journal of Management and Accounting*.
- [17] Robbyah, et al. (2021). Analysis of the Return and Risk of Investment in Insurance Companies Listed on the Indonesia Stock Exchange. *At-Taqaddum*.
- [18] Sureshkumar, V., & Balasubramanian, P. (2021). Risk and returns of Indian listed firms after demonetisation. *Cogent Economics & Finance*, 9.
- [19] Siagian, A.O., Wijoyo, H.W., & Cahyono, Y. (2021). The Effect of Debt to Asset Ratio, Return on Equity, and Current Ratio on Stock Prices of Pharmaceutical Companies Listed on the Indonesia Stock Exchange 2016-2019 Period. *Emerging Markets: Finance ejournal*.